KNOXVILLE -
The accepted SID abstract is titled 'Assessing the safety and toxicity of multi-dosed topical Rose Bengal Sodium (RBS) in a murine model of full-thickness cutaneous injury' (Control ID 4074036, Final ID 813, Current Category: Translational Studies and Early Preclinical to Clinical).
The work underlying this poster presentation is part of an ongoing sponsored research program with
About Provectus
Provectus's medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
FORWARD-LOOKING STATEMENTS
The information in this press release may include 'forward-looking statements,' within the meaning of
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company's filings with the
Contact:
Tel: 866-594-5999
(C) 2024 Electronic News Publishing, source